Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-01

Study Completion Date

2027-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Survival Outcomes of Lung Cancer

NCT03647098

Lung Cancer

RECRUITING

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

NCT05288569

Immune Checkpoint Inhibitors Lung Cancer

UNKNOWN

Assisting Pulmonary Disease Diagnosis With Ophthalmic Artificial Intelligence Technology

NCT05847894

Pulmonary Diseases Ophthalmological Diagnostic Techniques Artificial Intelligence

RECRUITING

An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

NCT07142057

LUNG CANCER

NOT_YET_RECRUITING

Risk Factors and Biomarkers for Post-tuberculosis Lung Damage

NCT05426720

Pulmonary TB

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single-center, non-randomized, clinical observational cohort study. It involves monitoring lung function at discharge (baseline, 0w), and at the 4th, 8th, 12th, 24th, and 48th weeks in patients recovering from severe pneumonia with AIDS. Basic demographic data, HIV RNA quantification, routine blood tests, blood biochemistry, arterial blood gas results, oxygenation index, immune function (CD3+, CD4+, CD8+ T cell counts), and imaging studies are also collected. Multifactorial logistic regression analysis is used to screen for clinical predictors of lung function decline in patients recovering from severe pneumonia

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AIDS Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Confirmed HIV infection;
2. Progression to the AIDS stage: CD4+ count \<200 cells/µL and/or occurrence of opportunistic infections associated with AIDS;
3. Age between 18 to 65 years;
4. Meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA).

Exclusion Criteria

1. Concurrent central nervous system lesions, severe liver disease, or cirrhosis;
2. Concurrent AIDS-related or non-related tumors;
3. Women who are pregnant or breastfeeding;
4. Presence of serious underlying diseases such as heart, lung, liver, kidney, etc.;
5. Alcohol abuse or drug use;
6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No